longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

ZMC

600216

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 14.71, within the reasonable range, cheaper than 66.36% of the time in the past 5 years, and the industry ranks 19/221, the industry Median 23.00.

14.71xP/E
¥12.33Stock price
¥0.84Earnings per share
14.71xP/E
Stock price¥12.33Earnings per share¥0.84

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
16.09x
Typical range
12.37x–25.64x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
Industry median 23.00x
010203040

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
Industry median 23.00x
0x40x80x120x160x200x
P/E ratio
Name/Symbol
000538SZYunnan Baiyao
17.22x7.62%¥89.93B
600196SHFOSUN PHARMA
17.01x13.38%¥57.68B
688578SHAllist
16.71x31.69%¥44.77B
000999SZCR Sanjiu
12.13x3.34%¥39.76B
600079SHHWHG
14.74x28.07%¥29.92B
000423SZDEEJ
16.43x12.09%¥29.33B
002603SZYILING PHARMACEUTICAL
18.45x16.88%¥25.38B
000513SZLIVZON GROUP
14.12x4.33%¥23.64B
600566SHJUMPCAN
12.44x--¥22.86B
002262SZNHWA
19.79x14.76%¥21.72B
000623SZJI LIN AO DONG
6.67x--¥21.11B
600535SHTASLY
17.13x20.77%¥20.95B
002773SZKHPG
17.55x--¥17.51B
600380SHJoincare
14.11x9.59%¥16.90B
600062SHCR Double-Crane
10.19x7.36%¥16.44B
600867SHTHDB
11.68x47.85%¥15.18B
600750SHCRJZ
16.21x6.25%¥14.19B
600267SHHISUN
14.96x39.13%¥13.14B
300573SZXingqi Pharmaceutical
16.01x--¥12.67B
605507SHGuobang Pharma
17.37x--¥12.28B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.